Search results

rivaroxaban (Xarelto)

Rivaroxaban co-administered with aspirin alone or with aspirin plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.

ticagrelor (Brilique)

Co-administered with aspirin, for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non ST elevation myocardial infarction [NSTEMI] or ST elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).

clopidogrel 75mg tablets (Plavix)

ST-segment elevation myocardial infarction (STEMI)

dabigatran (Pradaxa)

For the prevention of stroke and systemic embolism in adults with atrial fibrillation.

ticagrelor (Brilique)

Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction and a high risk of developing an atherothrombotic event.

prasugrel (Efient)

Prevention of atherothrombotic events in acute coronary syndrome

Clopidogrel (Plavix®)

Prevention of atherothrombotic events in acute coronary syndrome

bivalirudin (Angiox)

Acute coronary syndromes

bivalirudin (Angiox)

Anticoagulant in adult patients undergoing PCI, including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI.

rivaroxaban (Xarelto)

Co-administered with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events

April 2017 decisions news release

The Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has today published advice accepting five new medicines for routine use by NHSScotland.

February 2019 decisions news release

A medicine used to treat a rare blood cancer in children and young adults has today (Monday 11 February) been accepted by the Scottish Medicines Consortium (SMC) for use in NHSScotland.